|
CREBL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.762400E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.375500E-03 |
| Normal-vs-Stage2 |
8.826500E-02 |
| Normal-vs-Stage3 |
1.951420E-04 |
| Normal-vs-Stage4 |
1.236740E-04 |
| Stage1-vs-Stage2 |
3.879800E-01 |
| Stage1-vs-Stage3 |
1.626190E-01 |
| Stage1-vs-Stage4 |
8.400200E-02 |
| Stage2-vs-Stage3 |
8.543600E-02 |
| Stage2-vs-Stage4 |
4.211900E-02 |
| Stage3-vs-Stage4 |
5.440200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.4046999999956E-05 |
| Normal-vs-AfricanAmerican |
2.499200E-01 |
| Normal-vs-Asian |
1.697870E-03 |
| Caucasian-vs-AfricanAmerican |
1.390180E-01 |
| Caucasian-vs-Asian |
8.444000E-01 |
| AfricanAmerican-vs-Asian |
2.782200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.768830E-04 |
| Normal-vs-Female |
1.816830E-03 |
| Male-vs-Female |
1.691410E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.715960E-02 |
| Normal-vs-Age(41-60Yrs) |
2.960500E-04 |
| Normal-vs-Age(61-80Yrs) |
1.080670E-03 |
| Normal-vs-Age(81-100Yrs) |
4.635400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.598160E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.291000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.202450E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.305200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.140400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.810040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.631700E-02 |
| Classical-VS-Follicular |
5.110200E-02 |
| Classical-VS-Other |
8.998800E-01 |
| Classical-VS-Normal |
4.205100E-04 |
| Tall-VS-Follicular |
1.443230E-03 |
| Tall-VS-Other |
2.400200E-01 |
| Tall-VS-Normal |
3.66150000000731E-05 |
| Follicular-VS-Other |
6.050400E-01 |
| Follicular-VS-Normal |
1.827780E-01 |
| Other-VS-Normal |
1.860800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.044900E-03 |
| Normal-vs-N1 |
9.76609999980838E-07 |
| N0-vs-N1 |
6.643300E-03 |
|
|
